iData Insights

Ischemia - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 22, 2016 17:32 IST

Ischemia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ischemia - Pipeline Review, H2 2015, provides an overview of the Ischemias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173358/ischemia-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173358/ischemia-pipeline-review-h2-2015

Table of Contents

Introduction 8

Global Markets Direct Report Coverage 8

Ischemia Overview 9

Therapeutics Development 10

Pipeline Products for Ischemia - Overview 10

Pipeline Products for Ischemia - Comparative Analysis 11

Ischemia - Therapeutics under Development by Companies 12

Ischemia - Therapeutics under Investigation by Universities/Institutes 16

Ischemia - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Ischemia - Products under Development by Companies 20

Ischemia - Products under Investigation by Universities/Institutes 24

Ischemia - Companies Involved in Therapeutics Development 25

Alize Pharma SAS 25

Amyndas Pharmaceuticals LLC 26

AnGes MG, Inc. 27

Apceth GmbH & Co. KG 28

Athersys, Inc. 29

Baxalta Incorporated 30

Caladrius Biosciences, Inc. 31

Cellmid Limited 32

CoDa Therapeutics, Inc. 33

CohBar, Inc. 34

Cynata Therapeutics Limited 35

DNAVEC Corporation 36

GlaxoSmithKline Plc 37

Hemostemix Ltd 38

IntelliCell BioSciences Inc. 39

Juventas Therapeutics, Inc. 40

Kasiak Research Private Limited 41

Lixte Biotechnology Holdings, Inc. 42

Mesoblast Limited 43

Miltenyi Biotec GmbH 44

Mirrx Therapeutics A/S 45

Multi Gene Vascular Systems Ltd 46

NoNO, Inc. 47

Nyken BV 48

Pathfinder Cell Therapy, Inc. 49

Pharmicell Co., Ltd. 50

Pluristem Therapeutics Inc. 51

Protagenic Therapeutics Inc. 52

ReNeuron Group Plc 53

Sihuan Pharmaceutical Holdings Group Ltd. 54

Stempeutics Research Private Limited 55

Targazyme, Inc. 56

Taxus Cardium Pharmaceuticals Group Inc. 57

TikoMed AB 58

U.S. Stem Cell, Inc. 59

Vericel Corporation 60

ViroMed Co., Ltd. 61

Ischemia - Therapeutics Assessment 62

Assessment by Monotherapy Products 62

Assessment by Target 63

Assessment by Mechanism of Action 66

Assessment by Route of Administration 68

Assessment by Molecule Type 70

Drug Profiles 72

AB-002 - Drug Profile 72

ACP-01 - Drug Profile 74

AdipoCell - Drug Profile 76

Alda-1 - Drug Profile 78

Alecmestencel-T - Drug Profile 79

alferminogene tadenovec - Drug Profile 80

AntimiR-199a - Drug Profile 82

ASCT-01 - Drug Profile 83

Autologous Vascular Cells Therapy - Drug Profile 84

AZP-531 - Drug Profile 85

beperminogene perplasmid - Drug Profile 87

bucillamine - Drug Profile 92

CD-52 - Drug Profile 93

Cell Therapy for Critical Limb Ischemia - Drug Profile 94

Cell Therapy for Ischemia - Drug Profile 95

Cell Therapy for Ischemia - Drug Profile 96

Cellgram for Severe Lower Limb Ischemia - Drug Profile 97

Cinepazide Mesylate - Drug Profile 98

CLBS-12 - Drug Profile 99

CMK-103 - Drug Profile 100

daprodustat - Drug Profile 101

DVC1-0101 - Drug Profile 103

EP-80317 - Drug Profile 105

Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 106

Humanin - Drug Profile 107

ixmyelocel-T - Drug Profile 109

JVS-100 - Drug Profile 112

JVS-200 - Drug Profile 114

LB-100 - Drug Profile 115

LB-102 - Drug Profile 117

MicroRNA for Ischemia - Drug Profile 119

MPC-25IC - Drug Profile 120

MultiGeneAngio - Drug Profile 121

MultiStem - Drug Profile 123

NYK-1112 - Drug Profile 127

Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Disease - Drug Profile 128

Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders - Drug Profile 129

Pathfinder Cells - Drug Profile 130

Peptagon - Drug Profile 132

PLX-PAD - Drug Profile 133

PMC-6 - Drug Profile 137

Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 138

PT-00114 - Drug Profile 139

Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 140

Recombinant Protein for Critical Limb Ischemia - Drug Profile 141

Recombinant Protein for Ischemia - Drug Profile 142

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 143

Refacell-CLI - Drug Profile 144

Rejuveinix - Drug Profile 145

ReN-009 - Drug Profile 146

Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 147

Small Molecules for Ischemia and Reperfusion Injury - Drug Profile 148

Small Molecules for Renal Failure and Renal Ischemia - Drug Profile 149

Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 150

Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 151

Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 152

Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 153

Stem Cell Therapy for Cardiovascular Disease - Drug Profile 154

Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 156

Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 158

Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 159

Stempeucel - Drug Profile 160

Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 163

TM-700 - Drug Profile 164

TZ-101 - Drug Profile 165

VM-202 - Drug Profile 167

Ischemia - Recent Pipeline Updates 169

Ischemia - Dormant Projects 206

Ischemia - Discontinued Products 212

Ischemia - Product Development Milestones 213

Featured News & Press Releases 213

Appendix 218

Methodology 218

Coverage 218

Secondary Research 218

Primary Research 218

Expert Panel Validation 218

Contact Us 218

Disclaimer 219"

Read More http://www.idatainsights.com/reports-landing-page.php?id=173358/ischemia-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects